Quality by Design (QbD) MCQs With Answer

Introduction: Quality by Design (QbD) MCQs With Answer is a focused quiz resource designed for M.Pharm students studying Computer Aided Drug Development (MPH 203T). This set of questions emphasizes core QbD concepts — including QTPP, CQAs, CPPs, CMAs, design of experiments (DOE), risk assessment, process analytical technology (PAT), design space and control strategy — and links these with regulatory expectations (ICH Q8–Q10). The questions go beyond definitions to test application, interpretation of DOE results, selection of critical variables, and lifecycle management strategies. Each item includes concise options and the correct answer to support efficient revision and deeper understanding of QbD-driven product and process development.

Q1. What is the primary purpose of defining a Quality Target Product Profile (QTPP) in QbD?

• To list equipment and suppliers required for manufacturing
• To describe the intended quality, safety and efficacy characteristics of the final product
• To serve as a marketing document for product promotion
• To provide detailed batch manufacturing instructions

Correct Answer: To describe the intended quality, safety and efficacy characteristics of the final product

Q2. Which of the following best describes a Critical Quality Attribute (CQA)?

• A manufacturing parameter that can be adjusted during production
• A physical, chemical, biological or microbiological property that should be within an appropriate limit to ensure product quality
• A regulatory guideline outlining submission formats
• A marketing requirement for product labeling

Correct Answer: A physical, chemical, biological or microbiological property that should be within an appropriate limit to ensure product quality

Q3. In QbD terminology, what does CPP stand for and why is it important?

• Critical Process Parameter; it directly affects CQAs and must be controlled
• Continuous Production Protocol; it prescribes continuous manufacturing only
• Controlled Packaging Procedure; it focuses on secondary packaging quality
• Clinical Performance Predictor; it predicts patient outcomes

Correct Answer: Critical Process Parameter; it directly affects CQAs and must be controlled

Q4. Which statistical method is most appropriate for initially screening a large number of factors to identify those likely to be critical?

• Full factorial design at three levels
• Plackett–Burman or fractional factorial screening designs
• Repeated measures ANOVA only
• Simple linear regression for each factor separately

Correct Answer: Plackett–Burman or fractional factorial screening designs

Q5. What is the definition of “design space” as per ICH Q8(R2)?

• The single optimal operating point for a process
• The multidimensional combination of input variables and process parameters that have been demonstrated to provide assurance of quality
• The range of packaging materials acceptable for a product
• The physical space within which manufacturing equipment is arranged

Correct Answer: The multidimensional combination of input variables and process parameters that have been demonstrated to provide assurance of quality

Q6. Which tool is commonly used in QbD for systematic identification and ranking of potential failure modes and their causes?

• Pareto chart only
• Failure Mode and Effects Analysis (FMEA)
• Kaplan–Meier survival analysis
• Budget impact analysis

Correct Answer: Failure Mode and Effects Analysis (FMEA)

Q7. What role does Process Analytical Technology (PAT) play in a QbD framework?

• PAT is only used for final product testing after packaging
• PAT enables real-time monitoring and control of critical process parameters and CQAs
• PAT replaces the need for any quality control testing
• PAT is a regulatory reporting tool for submission to authorities

Correct Answer: PAT enables real-time monitoring and control of critical process parameters and CQAs

Q8. Which ICH guideline is primarily focused on pharmaceutical development and introduced QbD concepts?

• ICH Q3C
• ICH Q8
• ICH M4
• ICH S7

Correct Answer: ICH Q8

Q9. In DOE, what is the main advantage of using a central composite design (CCD) over a two-level factorial design?

• CCD is simpler and requires fewer runs than a two-level factorial
• CCD allows estimation of curvature (quadratic) effects and optimization within the design space
• CCD is only suitable for categorical factors
• CCD eliminates the need for randomization

Correct Answer: CCD allows estimation of curvature (quadratic) effects and optimization within the design space

Q10. How is criticality of a factor generally determined in the QbD risk assessment process?

• By selecting the factors that are easiest to measure
• By assessing the impact on CQAs, likelihood of occurrence and detectability using structured tools
• By choosing factors that have the smallest monetary cost
• By regulatory mandate of fixed critical factors for all products

Correct Answer: By assessing the impact on CQAs, likelihood of occurrence and detectability using structured tools

Q11. Which of the following best describes a Control Strategy under QbD?

• A detailed step-by-step SOP for laboratory testing only
• A planned set of controls derived from current product and process understanding to ensure product quality
• Only the automated control software used on manufacturing equipment
• A marketing plan to ensure consistent product uptake

Correct Answer: A planned set of controls derived from current product and process understanding to ensure product quality

Q12. What is the main benefit of establishing a design space for regulatory flexibility?

• Changes within the design space do not require prior regulatory approval
• Design space allows unlimited changes to formula without documentation
• Design space replaces the need for validation
• Design space eliminates the need for stability studies

Correct Answer: Changes within the design space do not require prior regulatory approval

Q13. Which of the following is a typical output of a DOE used in QbD?

• Identification of significant factors, interaction effects and a predictive model for responses
• A list of suppliers for raw materials
• Only a single-factor sensitivity analysis
• Final batch records for commercial manufacturing

Correct Answer: Identification of significant factors, interaction effects and a predictive model for responses

Q14. When applying QbD to formulation development, why is raw material variability considered a Critical Material Attribute (CMA)?

• Because raw materials are always more expensive than processes
• Because variability in material properties can directly influence CQAs and process performance
• Because CMAs are mandated by labeling requirements
• Because CMAs determine the marketing category of the product

Correct Answer: Because variability in material properties can directly influence CQAs and process performance

Q15. Which multivariate data analysis technique is commonly applied to PAT data for real-time process understanding?

• Principal Component Analysis (PCA)
• Kaplan–Meier estimator
• Fisher’s exact test
• Unpaired t-test only

Correct Answer: Principal Component Analysis (PCA)

Q16. What is the primary objective of performing robustness studies during QbD-based development?

• To identify the most profitable manufacturing site
• To determine the effect of small, purposeful variations on CQAs and establish acceptable operating ranges
• To validate cleaning procedures
• To finalize packaging artwork

Correct Answer: To determine the effect of small, purposeful variations on CQAs and establish acceptable operating ranges

Q17. Which regulatory concept supports continuous improvement and quality oversight throughout the product lifecycle in QbD?

• Change control freeze after approval
• Lifecycle approach integrating development, manufacturing, and continual improvement (ICH Q10)
• One-time process validation only
• Marketing authorization renewal every 3 months

Correct Answer: Lifecycle approach integrating development, manufacturing, and continual improvement (ICH Q10)

Q18. In scale-up, which principle is most consistent with QbD to ensure product quality is maintained?

• Maintaining geometric similarity of equipment regardless of process conditions
• Understanding and controlling CPPs and maintaining critical processing conditions rather than strict geometric similarity
• Scaling all times by the same factor without regard to heat or mass transfer
• Rewriting the QTPP for each scale

Correct Answer: Understanding and controlling CPPs and maintaining critical processing conditions rather than strict geometric similarity

Q19. Which of the following best describes MODR (Movement within the Design Space)?

• Any change outside the design space that needs immediate regulatory notification
• Changes within the approved design space that are considered non-reportable to regulators if justified
• The initial DOE performed during development
• A special type of analytical method validation

Correct Answer: Changes within the approved design space that are considered non-reportable to regulators if justified

Q20. What is the correct sequence of activities when implementing QbD in a new drug product development?

• Perform process validation → Define QTPP → Identify CQAs → Conduct DOE
• Define QTPP → Identify CQAs and CMAs/CPPs → Perform risk assessment and DOE → Establish control strategy and design space
• Submit regulatory application → Develop product → Monitor commercial batches
• Design packaging → Choose marketing strategy → Establish supply chain

Correct Answer: Define QTPP → Identify CQAs and CMAs/CPPs → Perform risk assessment and DOE → Establish control strategy and design space

Download